ValuEngine Upgrades Alliqua Biomedical (ALQA) to “Buy”
ValuEngine upgraded shares of Alliqua Biomedical (NASDAQ:ALQA) from a hold rating to a buy rating in a research report released on Wednesday morning.
Shares of NASDAQ ALQA traded down $0.07 during midday trading on Wednesday, hitting $1.67. The company’s stock had a trading volume of 644 shares, compared to its average volume of 25,779. Alliqua Biomedical has a 1 year low of $1.55 and a 1 year high of $2.78. The firm has a market cap of $8.51 million, a price-to-earnings ratio of -0.26 and a beta of 1.25.
Alliqua Biomedical (NASDAQ:ALQA) last issued its quarterly earnings results on Friday, August 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.64). Alliqua Biomedical had a negative return on equity of 235.69% and a negative net margin of 90.48%. The firm had revenue of $0.86 million during the quarter. As a group, analysts forecast that Alliqua Biomedical will post 5.14 EPS for the current fiscal year.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Read More: Short Selling
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.